Table I.
Characteristics of healthy volunteers participating in the NCT00119067 trial and available for ancillary study on genetic correlates.
| European- Americans (N=794) |
African-Americans (N=200) |
||
|---|---|---|---|
| Frequency (%) | Frequency (%) | p-valuea | |
| Sex: Female/Male (Ratio) | 409/385 (1.06) | 112/88 (1.27) | 0.291 |
| AGE AT ENROLLMENT | 0.006 | ||
| < 30 years | 176 (22.2) | 50 (25.0) | |
| 30 to 39 years | 172 (21.7) | 56 (28.0) | |
| 40 to 49 years | 250 (31.5) | 67 (33.5) | |
| 50 to 61 years | 196 (24.7) | 27 (13.5) | |
| VACCINATION GROUP | 0.703 | ||
| Group 1 | 160 (20.2) | 32 (16.0) | |
| Group 2 | 165 (20.8) | 40 (20.0) | |
| Group 3 | 151 (19.0) | 41 (20.5) | |
| Group 4 | 147 (18.5) | 39 (19.5) | |
| Group 5 | 171 (21.5) | 48 (24.0) | |
| CLINICAL SITE | <1.00E-15 | ||
| Rochester, MN | 208 (26.2) | 0 (0.0) | |
| Atlanta, GA | 130 (16.4) | 18 (9.0) | |
| Washington, DC | 125 (15.7) | 88 (44.0) | |
| Houston, TX | 149 (18.8) | 24 (12.0) | |
| Birmingham, AL | 182 (22.9) | 70 (35.0) | |
a
p-value from Chi-Square test. Group 1 received subcutaneous administration at 0, 2, 4, and 26 weeks. Group 2 received intramuscular administration at 0, 2, 4, and 26 weeks. Groups 3-5 received intramuscular administration at 0, 4, and 26 weeks.